PD98059

For research use only. Not for use in humans.

目录号：S1177

CAS No. 167869-21-8

PD98059 是一种非ATP竞争性的MEK抑制剂，无细胞试验中IC50为2 μM，特异性抑制MEK-1介导的MAPK激活；不直接抑制ERK1或ERK2。PD98059 是一种aryl hydrocarbon receptor (AHR)的配体并起到拮抗剂的功能。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1099.68	现货
10mg	RMB 1213.08	现货
50mg	RMB 3845.73	现货
200mg	RMB 5489.52	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PD98059发表文献386篇：

Immunity, 2021, S1074-7613(20)30538-0

PubMed: 33421362 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):17-32

PubMed: 30645973 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):329-344

PubMed: 28089908 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):840-855

PubMed: 29232556 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Cancer Cell, 2014, 26(5):754-69

PubMed: 25446900 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00269-0

PubMed: 33991485 ( click the link to review the publication )

Cell Rep, 2021, 35(13):109331

PubMed: 34192547 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):344

PubMed: 33795637 ( click the link to review the publication )

Oncoimmunology, 2021, 10(1):1897295

PubMed: 33763295 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.12936

PubMed: 33675143 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 214:112080

PubMed: 33677380 ( click the link to review the publication )

mSphere, 2021, 6(1)e00986-20

PubMed: 33408225 ( click the link to review the publication )

Front Oncol, 2021, 11:621154

PubMed: 33718179 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00173-3

PubMed: 33571522 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):302

PubMed: 34107979 ( click the link to review the publication )

Int J Biol Macromol, 2021, 180:129-142

PubMed: 33676979 ( click the link to review the publication )

J Gastroenterol Hepatol, 2021, 10.1111/jgh.15486

PubMed: 33694195 ( click the link to review the publication )

J Agric Food Chem, 2021, 10.1021/acs.jafc.1c00199

PubMed: 33749262 ( click the link to review the publication )

J Immunol Res, 2021, 2021:8483938

PubMed: 34222497 ( click the link to review the publication )

Int Immunopharmacol, 2021, 97:107628

PubMed: 34015701 ( click the link to review the publication )

Molecules, 2021, 26(8)2204

PubMed: 33921192 ( click the link to review the publication )
Int J Mol Med, 2021, 47(6)103

PubMed: 33907828 ( click the link to review the publication )

ACS Omega, 2021, 6(7):4759-4766

PubMed: 33644583 ( click the link to review the publication )

Pathol Oncol Res, 2021, 27:640936

PubMed: 34257606 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Biochem Pharmacol, 2021, 186:114479

PubMed: 33617842 ( click the link to review the publication )

J Ethnopharmacol, 2021, 270:113783

PubMed: 33421596 ( click the link to review the publication )

J Cell Physiol, 2021, 236(2):1375-1390

PubMed: 33128793 ( click the link to review the publication )

Am J Transl Res, 2021, 13(2):708-718

PubMed: 33594320 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):128

PubMed: 33888116 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz5913

PubMed: 32494742 ( click the link to review the publication )

Cell Rep, 2020, 7;30(1):215-228 e5

PubMed: 31914388 ( click the link to review the publication )

Part Fibre Toxicol, 2020, 17(1):46

PubMed: 32948194 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2795

PubMed: 33003386 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3216

PubMed: 33142778 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Glia, 2020, 10.1002/glia.23790

PubMed: 32036619 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000186RRR

PubMed: 32918765 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):28

PubMed: 31964421 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 12;2020:6837982

PubMed: 32318240 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00554-0

PubMed: 32910411 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Cancer Biol Med, 2020, 17(2):357-370

PubMed: 32587774 ( click the link to review the publication )
Chemosphere, 2020, 246:125774

PubMed: 31901531 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.16135

PubMed: 33247550 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Int J Mol Sci, 2020, 16;21(10):E3527

PubMed: 32429376 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32074942 ( click the link to review the publication )

Microorganisms, 2020, 11;8(3) pii: E389

PubMed: 32168837 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2020, 1;318(5):E613-E624

PubMed: 32154742 ( click the link to review the publication )

J Biol Chem, 2020, 295(3):673-689

PubMed: 31780563 ( click the link to review the publication )

Endocrinology, 2020, 161(12)bqaa190

PubMed: 33068422 ( click the link to review the publication )

Biomed Pharmacother, 2020, 23;128:110245

PubMed: 32454290 ( click the link to review the publication )

Biomed Pharmacother, 2020, 131:110724

PubMed: 32920518 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2020, 10.1152/ajpheart.00606.2020

PubMed: 33337962 ( click the link to review the publication )

Life Sci, 2020, 13;252:117666

PubMed: 32298737 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Food Funct, 2020, 11(12):10968-10978

PubMed: 33283791 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:105979

PubMed: 31771816 ( click the link to review the publication )

Eur J Pharmacol, 2020, 868:172886

PubMed: 31866407 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(1):21-33

PubMed: 31810383 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):171

PubMed: 32560675 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Cardiovasc Drugs Ther, 2020, 10.1007/s10557-020-07117-3

PubMed: 33242203 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):492-498

PubMed: 31677783 ( click the link to review the publication )

Onco Targets Ther, 2020, 2;13:2757-2769

PubMed: 32308411 ( click the link to review the publication )
Int J Gen Med, 2020, 13:1495-1507

PubMed: 33328759 ( click the link to review the publication )

Biomed Pharmacother, 2020, 121:109669

PubMed: 31766100 ( click the link to review the publication )

J Ethnopharmacol, 2020, S0378-8741(20)33532-7

PubMed: 33264660 ( click the link to review the publication )

Curr Eye Res, 2020, 10.1080/02713683

PubMed: 31951764 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):1064-1071

PubMed: 32070494 ( click the link to review the publication )

Neuroreport, 2020, 31(14):1007-1014

PubMed: 32815825 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30250-4

PubMed: 33129993 ( click the link to review the publication )

Brain Inj, 2020, 34(9):1277-1282

PubMed: 32749897 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15665

PubMed: 32705806 ( click the link to review the publication )

Bone, 2020, 141:115573

PubMed: 32768686 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Am J Chin Med, 2020, 48(1):223-244

PubMed: 32054305 ( click the link to review the publication )

Oral Dis, 2020, 10.1111

PubMed: 32176411 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:7165-7176

PubMed: 32801748 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Am J Transl Res, 2020, 12(7):3557-3576

PubMed: 32774719 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(8):4480-4493

PubMed: 32168416 ( click the link to review the publication )

Drug Deliv Transl Res, 2020, 7

PubMed: 32378175 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:1128

PubMed: 30850660 ( click the link to review the publication )

EMBO J, 2019, 38(12)

PubMed: 31068361 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-19-1555

PubMed: 31744816 ( click the link to review the publication )
BMC Med, 2019, 17(1):42

PubMed: 30782145 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Antioxid Redox Signal, 2019, 31(12):804-818

PubMed: 31088299 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

Emerg Microbes Infect, 2019, 8(1):934-945

PubMed: 31237474 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E75

PubMed: 30641867 ( click the link to review the publication )

Free Radic Biol Med, 2019, 141:21-33

PubMed: 31167117 ( click the link to review the publication )

J Clin Med, 2019, 8(6)

PubMed: 31238539 ( click the link to review the publication )

FASEB J, 2019,

PubMed: 30458112 ( click the link to review the publication )

Cell Commun Signal, 2019, 17(1):75

PubMed: 31307477 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(22):10610-10625

PubMed: 31785145 ( click the link to review the publication )

Cell Prolif, 2019, 52(3):e12575

PubMed: 30838710 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):80

PubMed: 30849996 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):350

PubMed: 31775870 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:4546975

PubMed: 31049135 ( click the link to review the publication )

Pharmacol Res, 2019, 143:73-85

PubMed: 30862605 ( click the link to review the publication )

J Recept Signal Transduct Res, 2019, 39(2):175-186

PubMed: 31354091 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):20779-20789

PubMed: 31025337 ( click the link to review the publication )

J Cell Physiol, 2019, 234(4):4504-4514

PubMed: 30246502 ( click the link to review the publication )

J Cell Physiol, 2019, 234(6):8846-8861

PubMed: 30317597 ( click the link to review the publication )

Front Oncol, 2019, 9:1244

PubMed: 31799197 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Sci Rep, 2019, 9(1):840

PubMed: 30696869 ( click the link to review the publication )
Int J Biol Sci, 2019, 15(8):1685-1695

PubMed: 31360111 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Biol Chem, 2019, 294(9):3284-3293

PubMed: 30573683 ( click the link to review the publication )

Int J Biol Macromol, 2019, 135:212-225

PubMed: 31108149 ( click the link to review the publication )

Gene, 2019, 683:195-209

PubMed: 30340049 ( click the link to review the publication )

Inflammopharmacology, 2019, 27(3):561-571

PubMed: 30251233 ( click the link to review the publication )

Mar Drugs, 2019, 17(1)E36

PubMed: 30626153 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:2653-2661

PubMed: 31114328 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Cell Signal, 2019, 54:17-26

PubMed: 30471465 ( click the link to review the publication )

Biomed Pharmacother, 2019, 116:109032

PubMed: 31163381 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):12500-12507

PubMed: 30834595 ( click the link to review the publication )

Life Sci, 2019, 229:1-12

PubMed: 30910647 ( click the link to review the publication )

Phytother Res, 2019, 33(8):2102-2117

PubMed: 31209984 ( click the link to review the publication )

Exp Cell Res, 2019, 379(1):65-72

PubMed: 30898547 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

Cell Cycle, 2019, 18(21):2928-2938

PubMed: 31496351 ( click the link to review the publication )

Chem Biol Interact, 2019, 310:108741

PubMed: 31299238 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(2):411-427

PubMed: 30483898 ( click the link to review the publication )

Am J Transl Res, 2019, 11(9):5824-5835

PubMed: 31632551 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(11):2344-2353

PubMed: 31498445 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105955

PubMed: 31678866 ( click the link to review the publication )
Toxicol In Vitro, 2019, 56:156-162

PubMed: 30677511 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30901941 ( click the link to review the publication )

Molecules, 2019, 24(6)

PubMed: 30889805 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3292-3304

PubMed: 31002345 ( click the link to review the publication )

Free Radic Res, 2019, 53(3):348-358

PubMed: 30773942 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2019, 10.1016/j

PubMed: 31422034 ( click the link to review the publication )

Environ Toxicol, 2019, 34(6):679-688

PubMed: 30801954 ( click the link to review the publication )

Am J Reprod Immunol, 2019, 81(1):e13073

PubMed: 30461130 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.110

PubMed: 31761326 ( click the link to review the publication )

Lipids Health Dis, 2019, 18(1):71

PubMed: 30909920 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3851718

PubMed: 30993112 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2019, 51(10):1056-1063

PubMed: 31555794 ( click the link to review the publication )

Med Sci Monit, 2019, 25:6491-6503

PubMed: 31465316 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7666-7674

PubMed: 31605603 ( click the link to review the publication )

Cell Biochem Biophys, 2019, 77(4):367-377

PubMed: 31659617 ( click the link to review the publication )

Cell Reprogram, 2019, 21(5):238-248

PubMed: 31369321 ( click the link to review the publication )

Life Sci, 2019, 235:116863

PubMed: 31513817 ( click the link to review the publication )

Biosci Rep, 2019, 39(11)

PubMed: 31548362 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)E840

PubMed: 31216681 ( click the link to review the publication )

Toxicol Lett, 2019, 301:98-107

PubMed: 30481581 ( click the link to review the publication )

Commun Biol, 2019, 2:359

PubMed: 31602408 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(8):846-857

PubMed: 31054961 ( click the link to review the publication )

Am J Chin Med, 2019, 913-931

PubMed: 31096773 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 200(5):617-627

PubMed: 30817168 ( click the link to review the publication )
Nutrients, 2019, 11(4)E782

PubMed: 30987344 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Oncogene, 2018,

PubMed: 29059160 ( click the link to review the publication )

Oncogene, 2018, 37(24):3275-3289

PubMed: 29551771 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):113

PubMed: 29866133 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 17;37(1):8

PubMed: 29343273 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)E439

PubMed: 30441794 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1140

PubMed: 30442927 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):278

PubMed: 29449539 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Br J Cancer, 2018, 119(9):1094-1105

PubMed: 30401978 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Hum Reprod, 2018, 33(11):2096-2106

PubMed: 30272163 ( click the link to review the publication )

J Cancer, 2018, 9(23):4449-4462

PubMed: 30519351 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Biol Lipids, 2018, 1863(2):177-190

PubMed: 29217477 ( click the link to review the publication )

Oxid Med Cell Longev, 2018, 2018:4572893

PubMed: 30538801 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2018, 1865(1):57-66

PubMed: 28964848 ( click the link to review the publication )

J Virol, 2018, 92(8)

PubMed: 29386287 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(7):3340-3352

PubMed: 29566307 ( click the link to review the publication )

Sci Rep, 2018, 8(1-:10070

PubMed: 29968778 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3120

PubMed: 29449636 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Inflammopharmacology, 2018, 10.1007/s10787-018-0492-y

PubMed: 29748880 ( click the link to review the publication )
Biomed Pharmacother, 2018, 105:320-325

PubMed: 29864620 ( click the link to review the publication )

Biomed Pharmacother, 2018, 105:282-289

PubMed: 29860220 ( click the link to review the publication )

Tissue Eng Part A, 2018, 24(5-6):502-515

PubMed: 28602124 ( click the link to review the publication )

J Cell Biochem, 2018, 119(1):300-313

PubMed: 28569433 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(41):10721-10728

PubMed: 30257559 ( click the link to review the publication )

Front Physiol, 2018, 9:765

PubMed: 29977209 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(2):109-117

PubMed: 25588050 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2018, 144(8):1487-1501

PubMed: 29858683 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Biochimie, 2018, 152:43-52

PubMed: 29960031 ( click the link to review the publication )

Molecules, 2018,

PubMed: 30513793 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Ann Hematol, 2018, 97(4):641-654

PubMed: 29350259 ( click the link to review the publication )

Neurochem Res, 2018, 43(10-:1963-1977

PubMed: 30136162 ( click the link to review the publication )

PLoS One, 2018, 13(9):e0203402

PubMed: 30192802 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0197422

PubMed: 29763460 ( click the link to review the publication )

PLoS One, 2018, 13(7):e0200878

PubMed: 30048489 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 496(4):1291-1295

PubMed: 29412164 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(3):155-165

PubMed: 29441602 ( click the link to review the publication )

Cell Biol Int, 2018, 42(5):598-607

PubMed: 29345412 ( click the link to review the publication )
Oncol Lett, 2018, 15(5):7443-7449

PubMed: 29731895 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):8442-8446

PubMed: 29805580 ( click the link to review the publication )

In Vivo, 2018, 32(3):549-554

PubMed: 29695559 ( click the link to review the publication )

In Vivo, 2018, 32(6):1361-1368

PubMed: 30348689 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):115

PubMed: 29866191 ( click the link to review the publication )

J Agric Food Chem, 2018, 66(31):8307-8318

PubMed: 29961319 ( click the link to review the publication )

Sci Total Environ, 2018, 643:496-506

PubMed: 29945085 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Dev Cell, 2017, 41(5):527-539.e5

PubMed: 28586645 ( click the link to review the publication )

Oncogene, 2017, 36(46):6359-6373

PubMed: 28745319 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(2):73-92

PubMed: 27650197 ( click the link to review the publication )

Cancer Lett, 2017, 395:31-44

PubMed: 28268166 ( click the link to review the publication )

Cancer Lett, 2017, 401:1-10

PubMed: 28483515 ( click the link to review the publication )

PLoS Pathog, 2017, 13(4):e1006321

PubMed: 28394926 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 41(5):1957-1969

PubMed: 28391263 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(9):1694-1704

PubMed: 28674151 ( click the link to review the publication )

J Neurochem, 2017, 142(2):231-245

PubMed: 28444734 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13319

PubMed: 29042627 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1663

PubMed: 28490734 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 171:318-327

PubMed: 28529129 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3281-3291

PubMed: 28651331 ( click the link to review the publication )

Immunol Cell Biol, 2017, 95(10):943-952

PubMed: 28878297 ( click the link to review the publication )
Biomed Pharmacother, 2017, 89:1037-1044

PubMed: 28292012 ( click the link to review the publication )

Biomed Pharmacother, 2017, 87:332-341

PubMed: 28064106 ( click the link to review the publication )

Brain Res Bull, 2017, 130:236-244

PubMed: 28189515 ( click the link to review the publication )

Exp Cell Res, 2017, 360(2):281-291

PubMed: 28919123 ( click the link to review the publication )

Chem Biol Interact, 2017, 270:1-8

PubMed: 28390675 ( click the link to review the publication )

Am J Transl Res, 2017, 9(6):2878-2890

PubMed: 28670376 ( click the link to review the publication )

Dev Comp Immunol, 2017, 76:392-402

PubMed: 28713009 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1036-1044

PubMed: 28000898 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Spine (Phila Pa 1976), 2017, 42(2):E61-E70

PubMed: 27270637 ( click the link to review the publication )

Neurochem Res, 2017, 10.1007/s11064-017-2174-3

PubMed: 28083849 ( click the link to review the publication )

PLoS One, 2017, 12(12):e0189920

PubMed: 29261770 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:627-643

PubMed: 28223821 ( click the link to review the publication )

J Neurol Sci, 2017, 372:171-177

PubMed: 28017206 ( click the link to review the publication )

DNA Cell Biol, 2017, 36(11):1029-1038

PubMed: 28945461 ( click the link to review the publication )

Exp Dermatol, 2017, 26(5):409-415

PubMed: 27762043 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 492(2):206-211

PubMed: 28821432 ( click the link to review the publication )

Food Nutr Res, 2017, 61(1):1368321

PubMed: 28970779 ( click the link to review the publication )

Microb Pathog, 2017, 10.1016/j.micpath

PubMed: 28131949 ( click the link to review the publication )

Cell Biochem Funct, 2017, 35(5):278-286

PubMed: 28749079 ( click the link to review the publication )

Cell Biol Int, 2017, 41(12):1307-1315

PubMed: 28816402 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:5985703

PubMed: 28167972 ( click the link to review the publication )

J Asthma, 2017, 54(5):467-475

PubMed: 27905842 ( click the link to review the publication )
Mol Med Rep, 2017, 16(2):1445-1450

PubMed: 29067463 ( click the link to review the publication )

Mol Med Rep, 2017, 16(2):1417-1424

PubMed: 28627644 ( click the link to review the publication )

Poult Sci, 2017, 96(9):3043-3051

PubMed: 28431078 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Drug Discov Ther, 2017, 11(4):212-217

PubMed: 28867754 ( click the link to review the publication )

Cell Prolif, 2017, 50(1)

PubMed: 27790820 ( click the link to review the publication )

Anesthesiology, 2017, 126(5):868-881

PubMed: 28121635 ( click the link to review the publication )

Oncotarget, 2017, 8(55):93878-93898

PubMed: 29212196 ( click the link to review the publication )

Oncotarget, 2017, 8(15):24237-24249

PubMed: 27458161 ( click the link to review the publication )

Menopause, 2017, 24(4):437-451

PubMed: 27922937 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55084-55093

PubMed: 28903404 ( click the link to review the publication )

Pflugers Arch, 2017, 469(9):1061-1071

PubMed: 28455747 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(4):524-34

PubMed: 26166769 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):640-50

PubMed: 27593484 ( click the link to review the publication )

Br J Dermatol, 2016, 175(6):1221-1231

PubMed: 27145925 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2435

PubMed: 27787522 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2412

PubMed: 27735943 ( click the link to review the publication )

Stem Cells, 2016, 34(11):2744-2757

PubMed: 27340942 ( click the link to review the publication )

Cell Physiol Biochem, 2016, 39(4):1317-28

PubMed: 27606810 ( click the link to review the publication )

Mol Oncol, 2016, 10(6):775-88

PubMed: 26842883 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:2572175

PubMed: 26962394 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(2):509-21

PubMed: 27186420 ( click the link to review the publication )
J Transl Med, 2016, 14:46

PubMed: 26861698 ( click the link to review the publication )

J Ethnopharmacol, 2016, 193:293-302

PubMed: 27553977 ( click the link to review the publication )

Prostate, 2016, 76(3):273-85

PubMed: 26499308 ( click the link to review the publication )

Exp Cell Res, 2016, 345(1):82-92

PubMed: 27237094 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 80:132-142

PubMed: 27702651 ( click the link to review the publication )

Cell Immunol, 2016, 310:63-70

PubMed: 27687530 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1635-44

PubMed: 26961889 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146554

PubMed: 26752289 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(2):330-7

PubMed: 27107695 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Pharm Biol, 2016, 54(10):2220-35

PubMed: 27049854 ( click the link to review the publication )

Exp Ther Med, 2016, 11(6):2413-2419

PubMed: 27284329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27874-88

PubMed: 27036049 ( click the link to review the publication )

Sci Rep, 2016, 6:30121

PubMed: 27444207 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43442-43460

PubMed: 27259276 ( click the link to review the publication )

Toxicol Res (Camb), 2016, 5(6):1573-1584

PubMed: 30090458 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10257-67

PubMed: 26831668 ( click the link to review the publication )

Tumour Biol, 2016, 37(3):3727-38

PubMed: 26468015 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48501-48516

PubMed: 27384485 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22623-31

PubMed: 26980707 ( click the link to review the publication )

Pflugers Arch, 2016, 468(11-12):2041-2051

PubMed: 27592222 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 27322144 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms9390

PubMed: 26399630 ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(12):2471-9

PubMed: 26331632 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2660-72

PubMed: 26609474 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

J Transl Med, 2015, 13(1):42

PubMed: 25638174 ( click the link to review the publication )

Sci Rep, 2015, 5:18314

PubMed: 26658818 ( click the link to review the publication )

J Nat Prod, 2015, 78(7):1689-96

PubMed: 26171689 ( click the link to review the publication )

Cytokine, 2015, 17:139-144

PubMed: ( click the link to review the publication )

Cytokine, 2015, 71(2):139-44

PubMed: 25461391 ( click the link to review the publication )

J Orthop Res, 2015, 10.1002/jor.22830

PubMed: 25731708 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 585:10-16

PubMed: 26363213 ( click the link to review the publication )

Toxicol In Vitro, 2015, 30(1 Pt B):521-8

PubMed: 26363202 ( click the link to review the publication )

Neurochem Res, 2015, 40(8):1609-19

PubMed: 26088686 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122109

PubMed: 25853521 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

Exp Biol Med, 2015, 10.1177/1535370215576312

PubMed: 25767191 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Acta Biochim Biophys Sin, 2015, 47(7), 1–9

PubMed: 26071572 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(3):134-42

PubMed: 25753185 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2015, 2015:307594

PubMed: 25802536 ( click the link to review the publication )

Tissue Cell, 2015, 47(3):301-10

PubMed: 25958163 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )
Genet Mol Res, 2015, 14(4):18325-33

PubMed: 26782480 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1428

PubMed: 25275589 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1187

PubMed: 24743742 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Thromb Haemost, 2014, 112(5):992-1001

PubMed: 25057055 ( click the link to review the publication )

Cell Microbiol, 2014, 16(9):1441-55

PubMed: 24779413 ( click the link to review the publication )

Biomed Pharmacother, 2014, 68(8):1037-43

PubMed: 25312822 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Toxicol Lett, 2014, 226(1):81-9

PubMed: 24495410 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2777-88

PubMed: 25335112 ( click the link to review the publication )

J Periodontal Res, 2014, 10.1111/jre.12193

PubMed: 24854880 ( click the link to review the publication )

PLoS One, 2014, 9(3):e85705

PubMed: 24633332 ( click the link to review the publication )

PLoS One, 2014, 9(1):e87311

PubMed: 24489893 ( click the link to review the publication )

PLoS One, 2014, 9(5):e94753

PubMed: 24787138 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):167-72

PubMed: 24582558 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 64(2):180-90

PubMed: 24705173 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2014, Zhang JL

PubMed: ( click the link to review the publication )
Oncol Lett, 2014, 8(4):1739-1744

PubMed: 25202402 ( click the link to review the publication )

Regul Pept, 2014, 194-195:41-8

PubMed: 25450576 ( click the link to review the publication )

Hepatology, 2013, 59(4):1262-72

PubMed: 23929627 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(1):37-48

PubMed: 24233399 ( click the link to review the publication )

Mol Cell Proteomics, 2013, 12(10):2952-68

PubMed: 23828894 ( click the link to review the publication )

J Thromb Haemost, 2013, 12(3):395-408

PubMed: 24354620 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2013, 144PA:223-227

PubMed: 24514755 ( click the link to review the publication )

Mol Cell Endocrinol, 2013, 375(1-2):89-96

PubMed: 23707617 ( click the link to review the publication )

Cell Signal, 2013, 26(3):512-20

PubMed: 24308969 ( click the link to review the publication )

Microbes Infect, 2013, 15(2):105-14

PubMed: 23164610 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82610

PubMed: 24340049 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70732

PubMed: 23967093 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

PLoS One, 2013, 8(12):e85032

PubMed: 24376862 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63890

PubMed: 23667687 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Genetic Syndromes & Gene Therapy, 2013, 4:6

PubMed: ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Microbiol Immunol, 2012, 56(11):782-8

PubMed: 22938101 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Atheroscler, 2011, 218(2):486-92

PubMed: 21782178 ( click the link to review the publication )
Int J Mol Med, 2011, 28(1):115-9

PubMed: 21455558 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

MEK抑制剂选择性比较

生物活性

产品描述

特性

PD98059不会抑制已经被c-Raf磷酸化的 MEK1

靶点

AhR ^[1] (Cell-free assay)	MEK1 ^[1] (Cell-free assay)
1 μM	2 μM

体外研究

PD98059 要么抑制本底的MEK1，要么抑制一种被部分激活的MEK突变体，该突变体是 218 和 222号位上丝氨酸突变为谷氨酸后形成的(MEK-2E)， IC50 为2 μM. PD98059 不会抑制JNK和P38这两个 MAPK 的同系物. PD98059会高度选择性的抑制MEK, 因为对其它包括Raf 激酶, cAMP-依赖性激酶, 蛋白激酶C, v-Src, 表皮生长因子 (EGF) 受体激酶, 胰岛素受体激酶, PDGF 受体激酶, 和磷脂酰肌醇(-3)激酶等在内的一系列激酶都没有抑制性。 PD98059 会抑制经过PDGF刺激而活化的MAPK 和胸苷进入 3T3 细胞， IC50分别为 ~10 μM 和 ~7 μM ^[1]。PD98059可以有效地阻止 MEK1 被Raf 或者MEK 激酶活化， IC50为4 μM, 可以微弱地抑制MEK2被 Raf 活化， IC50 为50 μM。在KB 和 PC12 细胞中, PD98059 不会抑制MKK4 和RK激酶这两个参与压力和白细胞介素-1介导的激酶级联反应的MEK的同系物的活化，在Swiss 3T3 细胞中也不会通过胰岛素或者表皮生长因子抑制p70 S6 激酶的活化^[2]。PD98059会在不改变细胞生存能力的情况下完全阻断神经生长因子(NGF)诱导的 PC12 细胞的分化^[3] 。PD98059会以剂量依赖性的方式抑制培养在含有破骨细胞分化因子培养基中的 RAW264.7细胞的增值，进而导致TRAP阳性细胞数量明显下降^[6]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A2780	M4TMXGZ2dmO2aX;uJGF{e2G7	M1P1d\|IxyqEQvF2=	M1v6dlEhcA>?		NFTMOIljdG:la4OgSHRETC2rbnT1Z4VlKESUNTDlfJBz\XO\|aX;u	NWDX[Xk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PVY5PjJpPkKzOlk3QDZ{PD;hQi=>
AML 1#	M4rN[mFxd3C2b4Ppd{BCe3OjeR?=	MUCyNOKh\|ryP	NHj6fGwyOiCq		NV60WoJP\W6qYX7j[ZMh[2WubDDhdI9xfG:\|aYOgbY5lfWOnZDDifUBUOQ>?	NGXTSlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewOlY6OSd-MkO3NFY3QTF:L3G+
KG-1	M2[xbGFxd3C2b4Ppd{BCe3OjeR?=	NHfXcG8zOMLizszN	M4fyeFEzKGh?		MYrlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGOx	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyNk[5NUc,OjN5ME[2PVE9N2F-
HUVECs	NIrvPZJCeG:ydH;zbZMhSXO\|YYm=	NUXPcnpyOi92IN88US=>	M{izTlI1NzR6IHi=		M3GzRYlv\HWlZYOgZ4VtdCCmZXH0bC=>	M3L2c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{C3OVIxLz5{M{ewO\|UzODxxYU6=
HepG2	M1LyZmZ2dmO2aX;uJGF{e2G7	MXOyNOKh\|ryP	MWWyOEBp		MYDpcohq[mm2czD0bIUhUE9vMTDwdo91\WmwIHX4dJJme3Orb36gZ48ufHKnYYTl[EB4cXSqIH3leIZwem2rbh?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{[wPUc,OjN5MEe2NFk9N2F-
NB4	NH;Rd3hCeG:ydH;zbZMhSXO\|YYm=	MlG1NVAwOjBxNkCg{txO	MoTPNU42KGh?	NVy2VHRYTE2VTx?=	NVf0T5Js\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDQZYNtcXSjeHXs	NGHEbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ezOVU1OSd-MkO3N\|U2PDF:L3G+
BxPC-3 cells	NXrYUmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\2N\|IxyqEQvF2=	NIXmOGgxNjViaB?=		M4K3dIlvcGmkaYTzJHZGT0ZvQT3y[Yd2dGG2ZXSgTHVXTUNiZ4Lve5RpKGGwZDD0eYJmKG[xcn3heIlwdiCrbnT1Z4VlKGK7IGDBVk0zKEGS	M1fKXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{[0NFQ3Lz5{M{e2OFA1PjxxYU6=
MKN45	MnmxRZBweHSxc3nzJGF{e2G7	NFjCWo8yOCEQvF5CpC=>	Mn7PNlQhcA>?		MVLpcoNz\WG\|ZYOgeIhmKESDUGStbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkW4PEc,OjN5OUK1PFg9N2F-
SGC7901	Mnj6RZBweHSxc3nzJGF{e2G7	Ml3CNVAh\|ryPwrC=	M4m1W\|I1KGh?		MkXNbY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN?	MlPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK1PFgoRjJ\|N{myOVg5RC:jPh?=
MKN45	MoXISpVv[3Srb36gRZN{[Xl?	MXGxNEDPxE4EoB?=	MlnRNlQhcA>?		M2rCcolvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJBpd3OyaH;yfYxifGWmIFXST\|EwOg>?	NFn0T4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPYR2syOCEQvF5CpC=>	NYPzVJdrOjRxNEivO\|IhcA>?		M{LlPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW	NXTtV49kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI2QDhpPkKzO\|kzPTh6PD;hQi=>
MKN45	NEm0blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XSd\|ExKM7:TdMg	NUDwNXVDOjRxNEivO\|IhcA>?		MVPpcohq[mm2czDj[YxtKGe{b4f0bEBkdy22cnXheIVlKHerdHigSGFRXA>?	NFzYUpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
SGC7901	Mnf1SpVv[3Srb36gRZN{[Xl?	NFX6eIoyOCEQvF5CpC=>	M1nVNlI1KGh?		MXjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM\|I>	NITMc\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlU5QCd-MkO3PVI2QDh:L3G+
HUASMCs	MVPGeY5kfGmxbjDBd5NigQ>?	Mof0NVAh\|ryPwrC=	MUOyOEBp		NYG1PG13\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N\|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg	NY\FdmtYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVY1PjhpPkKzPFE3PDZ6PD;hQi=>
HUASMCs	NWHV[lQ{TnWwY4Tpc44hSXO\|YYm=	MYSxNEDPxE4EoB?=	M2rLZlI1KGh?		MVrpcohq[mm2czDBcochUUlvaX7keYNm\CCHUluxM\|IheGixc4Doc5J6dGG2aX;uJIxmfmWu	MmjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MU[0OlgoRjJ\|OEG2OFY5RC:jPh?=
EPOR/CR3	NYi1SJdbTnWwY4Tpc44hSXO\|YYm=	NVziSpFUPTEEoN88US=>	MVyzJIg>		MmKwdoVlfWOnczDFVG8h[W6mL3;yJGlNNTNvaX7keYNm\CC2aHWgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wwrC=	M{K0SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEKwO\|MyLz5{M{iyNFc{OTxxYU6=
NB4	NV36VGhJTnWwY4Tpc44hSXO\|YYm=	MYKxNEDPxE4EoB?=	NELxeYg4OiCq	M3ryNGROW09?	NFfidFdqdmirYnn0d{Bl[XOjdHnubYIucW6mdXPl[EBETDFzYjDlfJBz\XO\|aX;u	NHyzb5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HL60	NX3IRndTTnWwY4Tpc44hSXO\|YYm=	M2HTZVIxyqEQvF2=	MkizO\|IhcA>?	MoHQSG1UVw>?	M3TYeYlvcGmkaYTzJIRie2G2aX7pZk1qdmS3Y3XkJGNFOTGkIHX4dJJme3Orb36=	NHTZVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iyOVU5PSd-MkO4NlU2QDV:L3G+
HUVECs	MWHGeY5kfGmxbjDBd5NigQ>?	NW\MeFVMOjVizszN	NXm4elJpOSCq		MonsbY5kemWjc3WgUmYu\|rqEIIC2OUBvfWOuZXHyJJRz[W6\|bH;jZZRqd25?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlyMUCwPEc,OjN7MEGwNFg9N2F-
LNCaP	Mn\RSpVv[3Srb36gRZN{[Xl?	NVL4OYtTOTBizszNxsA>	MlrYNUBp		M2XyZYRm[3KnYYPld{B1cGViRVfGJJVxemWpdXzheIVlKHBvWVKtNS=>	MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{izNVgoRjJ\|OEO4N\|E5RC:jPh?=
HL-60	NWfucmk4SXCxcITvd4l{KEG\|c3H5	NYPIbJJ7PTEEoN88US=>	M4Ht[VEhcA>?		NIHHVVJz\XOldXXzJGJCOTR3IH3l[IlifGWmIHHwc5B1d3Orcx?=	NETydog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m0PFc2OSd-MkO5OFg4PTF:L3G+
HepG2	MnfESpVv[3Srb36gRZN{[Xl?	NF[wNXg1OCEQvF2=	NGnmfnA3NzF{IHi=		MkD6bY5pcWKrdIOgeIhmKGmwY4LlZZNmKG:oIICtSXJMOSCjbnSgdE1kNUq3bjDwdo91\WmwIHX4dJJme3Orb36gZpkhWEx?	NXvhbWZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OFI5PTFpPkKzPVQzQDVzPD;hQi=>
HPAF-II	MXnGeY5kfGmxbjDBd5NigQ>?	MnfhNVAh\|ryPwrC=	M{PGVFYhcA>?		NX7PfGJXcW6lcnXhd4UhdWmULUG0N{BmgHC{ZYPzbY9v	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{exNEc,OjN7N{O3NVA9N2F-
BxPC-3	M33PO2Z2dmO2aX;uJGF{e2G7	NVfPU2huOTBizszNxsA>	NVPUfnk1PiCq		M1ntTolv[3KnYYPlJI1qWi1zNEOg[ZhxemW\|c3nvci=>	Mo[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7N{O3NVAoRjJ\|OUezO\|ExRC:jPh?=
COLO205	M2jWU2Fxd3C2b4Ppd{BCe3OjeR?=	NET5XpYyOC9{MD:0NEDPxE1?	NXKxdIxoOjRiaB?=		MkfnbY5lfWOnczDEUmEhdGGmZHXyJIZwem2jdHnvci=>	NX;wXnlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVkyODhpPkK0NFE6OTB6PD;hQi=>
G292	NUXiZml5SXCxcITvd4l{KEG\|c3H5	MX[zNOKh\|ryP	MlrqNkBp		NYPY[5pMemW\|dH;y[ZMh[2Gyc3HpZ4lvNWmwZIXj[YQh[2WubDDk[YF1cA>?	MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUK5N\|AoRjJ2MEGyPVMxRC:jPh?=
SGC7901	NUTHTplOSXCxcITvd4l{KEG\|c3H5	NYHzVZROOjEEoN88US=>	NVKwPZVvOSCq		MmrNbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhUU[QLd8xxsBidmRiNfMAtk1FTlWU	NWXNW4F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNlc4PTBpPkK0NFI4PzVyPD;hQi=>
MGC803	NYD1[nRnSXCxcITvd4l{KEG\|c3H5	NWXPV\|VlOjEEoN88US=>	MXyxJIg>		NVPaXmp6cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB{N{e1NEc,OjRyMke3OVA9N2F-
HPMC	MXPBdI9xfG:\|aYOgRZN{[Xl?	MYCxNOKh\|ryP	MXeyOOKhcA>?		M3;pOJJmfmW{c3XzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhUEeSRGO=	Mm\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEK4N\|goRjJ2MESyPFM5RC:jPh?=
HCT-8	MmDZRZBweHSxc3nzJGF{e2G7	MonNNVDDqM7:TR?=	MnrqNlTDqGh?		Mkj4[IVkemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgOU1HXQ>?	MnztQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUW4OlMoRjJ2MEm1PFY{RC:jPh?=
HPMC	NWXYU4JLTnWwY4Tpc44hSXO\|YYm=	M4HlO\|ExyqEQvF2=	MoTQOFghcA>?		NYLqSWNKemW4ZYLz[ZMhfGinIHPoZY5o\XNiaX6gZ4VtdCCvb4LwbI9td2e7IHnu[JVk\WRiYomgTGdRTFN?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2MkizPEc,OjRyNEK4N\|g9N2F-
A549	MUnGeY5kfGmxbjDBd5NigQ>?	NHfaNW02OMLizszN	NXjwVoJWOiCq		MlXOZoxw[2u\|IFXST{BxcG:\|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R	NVXsZZRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlc4OjdpPkK0NFY4PzJ5PD;hQi=>
Caco-2	M4j3c2Fxd3C2b4Ppd{BCe3OjeR?=	NUGzWmdXOTEEoN88US=>	NHT3cJEzPMLiaB?=		MmHQ[IVkemWjc3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgOU1HXQ>?	M1i1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1PFY{Lz5{NEC5OVg3OzxxYU6=
AGS	MVHGeY5kfGmxbjDBd5NigQ>?	NGTSU\|QyOCEQvF5CpC=>	Mn36NE42KGh?		MlX6bY5pcWKrdIOgeIhmKHWycnXneYxifGmxbjDv[kB1cGViSVytPEBo\W6n	NWnNNWZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNFYyPjZpPkK0NVA3OTZ4PD;hQi=>
Ca9-22	Mlz1SpVv[3Srb36gRZN{[Xl?	NGDSSWE{KM7:TR?=	NFzaOIkyNzJiaB?=		M{PlcJJm\HWlZYOgTIJTNWmwZIXj[YQhSVSILUKgdIhwe3Cqb4L5cIF1cW:w	MlzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMk[1N\|IoRjJ2MUK2OVMzRC:jPh?=
Ca9-22	MljHSpVv[3Srb36gRZN{[Xl?	MWKzJO69VQ>?	NILMTo0yKGh?		Mlf1ZYJwdGm\|aHXzJJRp\SCjYnnsbZR6KG:oIFjiVkB1dyCrbnT1Z4UhUUxvODDwdo9lfWO2aX;u	M3HBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK2OVMzLz5{NEGyOlU{OjxxYU6=
HAECs	NFewOG9HfW6ldHnvckBCe3OjeR?=	MV:xNEDPxE1?	MWWxJIg>		MVtCpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>?	NHH6b\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzOFY2Pyd-MkSxN\|Q3PTd:L3G+
Caco-2	NH3wdYpHfW6ldHnvckBCe3OjeR?=	NX3tXWdiPTEEoN88US=>	M130Z\|Q5cA>?	NXjVT\|BLTE2VTx?=	NHzhNXlmdmijbnPld{B1cGVibWLORUBt\X[nbIOgc4bDqFOFTl6xRUxHYFmGMz\|CpGxEXC{EoFzPXEzDqEiLRkPBMOKhYkdzNj\|CpHBFTT[DwrDhcoTDqEyJQVzTNVbDqGenbnXzxsBkdy22cnXheIVlKHerdHigSIV5	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4MU[5OUc,OjRzNkG2PVU9N2F-
MCF-7	NHu0PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K0SFExKM7:TR?=	NXvVVJR1PDiq	MofsSG1UVw>?	MULy[ZZmenOnczDCUmYucW6mdXPl[EBk\WyuIHP5Z4xmKGG{cnXzeC=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF4M{SwOEc,OjRzNkO0NFQ9N2F-
SMMC7721	NEHVZXVHfW6ldHnvckBCe3OjeR?=	M1\zbFI2NzVyIN88US=>	NUjab25{OjRiaB?=		M4HKPJN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM\|LDqA>?	NV70XJM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOlgxPTZpPkK0NVY5ODV4PD;hQi=>
SGC7901	MYHBdI9xfG:\|aYOgRZN{[Xl?	M3XIW\|UxyqEQvF2=	MoDjNlQwPDhxN{KgbC=>	NFfMd2NFVVOR	NHTNVZBqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT\|Ihe2iUTlG=	M2CweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe4NlQxLz5{NEG3PFI1ODxxYU6=
7721	MmrjRZBweHSxc3nzJGF{e2G7	MVGzNEDPxE1?	MWm1JIQ>		Mlzr[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=>	NVzrbGxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVEzPTNpPkK0NlEyOjV\|PD;hQi=>
DLD-1	M{DqOGZ2dmO2aX;uJGF{e2G7	NWXEXFNuOjEEoN88US=>	NHXNb5I1QCCq		NIfCUZdz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	M3G3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxOVgyLz5{NEKxNVU5OTxxYU6=
HT-29	NEHQRnNHfW6ldHnvckBCe3OjeR?=	NEXoNWUzOMLizszN	MmnuOFghcA>?		NEjQZphz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM>	M4j6d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxOVgyLz5{NEKxNVU5OTxxYU6=
7402	M17JNWFxd3C2b4Ppd{BCe3OjeR?=	NYXIS3REOzBizszN	NUDsXm92PSCm		NHHkXmVl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v	M2j3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxNlU{Lz5{NEKxNVI2OzxxYU6=
MCF-7	MXTGeY5kfGmxbjDBd5NigQ>?	M3G2WlIxKM7:TR?=	NFi1dZYyKGh?		NH[zfJhi[m:uaYPo[ZMh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUlugZ48ufHKnYYTt[Y51KHerdHigZ49vcnWpYYTl	NUXKZ\|FkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNVYzQDlpPkK0NlE3Ojh7PD;hQi=>
MCF-7	MVfBdI9xfG:\|aYOgRZN{[Xl?	NHr6NnQzOCEQvF2=	NWLkeIJIOSCq		MonabY5kemWjc3XzJINie3Cjc3WtPUBmdnq7bXWgZYN1cX[rdIm=	NIXSUJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxOlI5QSd-MkSyNVYzQDl:L3G+
CRL-2302	MVrGeY5kfGmxbjDBd5NigQ>?	MWmyNEDPxE1?	MoLBNE42KGh?		MoLubY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0	M4TIXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkK3PVE5Lz5{NEKyO\|kyQDxxYU6=
ARPE-19	M1PpXGZ2dmO2aX;uJGF{e2G7	M3nMZ\|IxKM7:TR?=	NGLle5MxNjViaB?=		M4Dsc4lvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=>	NFmzU4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKyO\|kyQCd-MkSyNlc6OTh:L3G+
MG-63	NIH1SppHfW6ldHnvckBCe3OjeR?=	NU\IUWVuOjBizszN	MXmwMlUhcA>?		MU\icI9kc3NidHjlJGNJNWmwZIXj[YQheGixc4Doc5J6dGG2ZXSgSWxMOSCycn;0[YlvKGW6cILld5Nqd25?	NVPWOIk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyN\|k3PDBpPkK0NlM6PjRyPD;hQi=>
SGC-7901	M{\SbWFxd3C2b4Ppd{BCe3OjeR?=	NUfSW\|VVOjBizszN	MW[yOEBp		NWjBOmxIcW6qaXLpeJMhS1BvbXXkbYF1\WRiYYDvdJRwe2m\|	NH6ybIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0NVM2OSd-MkSyOFE{PTF:L3G+
NUGC2	MYnGeY5kfGmxbjDBd5NigQ>?	NX;V[pE2PTBizszN	NVPBfWU6PDhiaB?=	MkLZSG1UVw>?	NEjZW2RqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz	NEnpW4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
NUGC3	MXjGeY5kfGmxbjDBd5NigQ>?	M371U\|UxKM7:TR?=	M4LwdFQ5KGh?	MVLEUXNQ	M3y4Rolv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	NHH1WFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KATOIII	MWjGeY5kfGmxbjDBd5NigQ>?	NFXaZVU2OCEQvF2=	M3TV[lQ5KGh?	M2T1dGROW09?	MWLpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW\|	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NECyN{c,OjR{NESwNlM9N2F-
NCI-N87	NIrLcYVHfW6ldHnvckBCe3OjeR?=	MWW1NEDPxE1?	NX7udYV7PDhiaB?=	M1npS2ROW09?	M4L0[4lv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO=	NV3QdZhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
OE19	NGnKPI5HfW6ldHnvckBCe3OjeR?=	NH;RNmo2OCEQvF2=	NGS4PIM1QCCq	MXXEUXNQ	NYHWPXpDcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	MoDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
MKN7	MXLGeY5kfGmxbjDBd5NigQ>?	NFH6dHc2OCEQvF2=	M1v0RVQ5KGh?	NVPrdGhMTE2VTx?=	NXT0dlNXcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=>	NWO4d4dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE4	NF76OYNHfW6ldHnvckBCe3OjeR?=	NFTFVIo2OCEQvF2=	M{f0SFQ5KGh?	MUnEUXNQ	NEXPVpV2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	NWPoZZE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
KYSE30	MojvSpVv[3Srb36gRZN{[Xl?	MlHTOVAh\|ryP	NITF[3E1QCCq	MV\EUXNQ	NXro[XRNfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO\|IFm=	MnnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE5	NFjFXWtHfW6ldHnvckBCe3OjeR?=	MYO1NEDPxE1?	MVe0PEBp	NG\mZnBFVVOR	NH\xbmx2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	NUO1cWtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	MnPySpVv[3Srb36gRZN{[Xl?	M{nPSlUxKM7:TR?=	NI[zW3M1QCCq	NELiTGdFVVOR	NFS1d5F2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKTFGgZ4xie3NiSR?=	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NESwNlMoRjJ2MkS0NFI{RC:jPh?=
TE3	MWLGeY5kfGmxbjDBd5NigQ>?	NF3hZlU2OCEQvF2=	MnfZOFghcA>?	MVLEUXNQ	MY\1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>?	NGLCN4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK0OFAzOyd-MkSyOFQxOjN:L3G+
KYSE30	MknDSpVv[3Srb36gRZN{[Xl?	MXGyNE82OC9zMECg{txO	M4PLUVQ5KGh?	NGrtb2NFVVOR	NVPId5pmcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUTTcod6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE1	NHzPXW1HfW6ldHnvckBCe3OjeR?=	Mo\pNlAwPTBxMUCwJO69VQ>?	MXm0PEBp	NEnQNHBFVVOR	NXG4blJzcW6qaXLpeJMheC2HcnugZY5lKHexcoTtZY5vcW5iZH;3cpJm\3WuYYTl[EBxNUGtdDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NWTRWI42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
TE4	MonFSpVv[3Srb36gRZN{[Xl?	Mn7xNlAwPTBxMUCwJO69VQ>?	NGm4clY1QCCq	NU\zb2FmTE2VTx?=	NGflWIZqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NYDkTnMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOFQxOjNpPkK0NlQ1ODJ\|PD;hQi=>
HT29	MknKSpVv[3Srb36gRZN{[Xl?	M4O0ZVExKM7:TR?=	M3jib\|IhcA>?		NXHHeol4cW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	NVXWOWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlUzQTNpPkK0NlY2Ojl\|PD;hQi=>
HepG2	Mk\wRZBweHSxc3nzJGF{e2G7	NYj6fGs{OjBizszN	MoDmNlQhcA>?		NHvxN4hqdmirYnn0d{BGWktzL{KgdIhwe3Cqb4L5cIF1cW:wIHHu[EBmdmijbnPld{BXSjFvaX7keYNm\CCjcH;weI9{cXN?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2N{mwPUc,OjR{NEe5NFk9N2F-
HepG2	NVvGUFdRTnWwY4Tpc44hSXO\|YYm=	MVyyNEDPxE1?	NUm2Rmh{OiCq		MXTlcohidmOnczDWRlEucW6mdXPl[EBHV1iRM3GgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7	M{j0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkS3PVA6Lz5{NEK0O\|kxQTxxYU6=
MC-3	MXvBdI9xfG:\|aYOgRZN{[Xl?	MUmxNEDPxE1?	MluyNlQhcA>?		Mki3dI91\W62aXH0[YQhVUWVQz3pcoR2[2WmIHHwc5B1d3OrczDpckAh[2WubIO=	NYPpTWlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO\|A2OjNpPkK0NlcxPTJ\|PD;hQi=>
Raji	MoHKSpVv[3Srb36gRZN{[Xl?	NVy5VWExOTBizszN	NHfCelQyKGh?		NUXXWFlI[myxY3vzJIh{SkGIRjDpcoR2[2WmIFXyb\|EwOiCyaH;zdIhwenmuYYTpc44>	NYq1epZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlk3OzBpPkK0NlY6PjNyPD;hQi=>
Raji	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nJ[\|ExKM7:TR?=	MVixJIg>		MUXpcohq[mm2czD0bIUh[mG\|YXygc5IhcHOEQV\GMZN1cW23bHH0[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdIm=	M3XadlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[5OlMxLz5{NEK2PVY{ODxxYU6=
A549	NX;SSop1TnWwY4Tpc44hSXO\|YYm=	NYe0NFVZOzBizszN	MXKwMlUhcA>?	Ml3tSG1UVw>?	NFjSXYpqdmirYnn0d{B1cHKxbXLpck1qdmS3Y3XkJGMwTUKSzsKgWIhzOjN3wrDwbI9{eGixconsZZRqd25?	MojCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{e2PVYoRjJ2Mke3Olk3RC:jPh?=
HCSMCs	NVnm[4FUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33Te\|ExKM7:TR?=	MkHoNlQhcA>?		M4LuTYJtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w	M3z1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{GyN\|gyLz5{NEOxNlM5OTxxYU6=
PANC-1	NVvrS4hFTnWwY4Tpc44hSXO\|YYm=	Ml3LNlAh\|ryP	MkLPOFghcA>?		NYHEfWhGcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yh\|pR4RDDpckBz\XOyb37z[UB1dyC2aHWgVHBCWs72wrDh[49vcXO2wrC=	NI\aOFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5OFE{Oyd-MkSyPVQyOzN:L3G+
A549	M2G1cGZ2dmO2aX;uJGF{e2G7	M3HXe\|MxKM7:TR?=	MofnNE42KGh?	MnuySG1UVw>?	NILLTlJqdmirYnn0d{B1cGVidHjyc41jcW5vaX7keYNm\CCLTD24M2NZS0x6LVz1Z{Bi[3Srdnn0fS=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5N{[5Okc,OjR{N{e2PVY9N2F-
SW480	NWfxXm9bTnWwY4Tpc44hSXO\|YYm=	MY[xNEDPxE1?	MWSyNEBp	Mlu0SG1UVw>?	NWPsW\|lOe3WycILld5NmeyC2aHWgR3JVKGGldHn2bZR6	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MkSzOlYoRjJ2M{K0N\|Y3RC:jPh?=
HEK 293	M4LPe2Z2dmO2aX;uJGF{e2G7	MmqwNVAh\|ryP	NUHIfoRFPSCq	NGKzNHlFVVOR	MUHpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh\|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36=	M{m0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0N\|Y3Lz5{NEOyOFM3PjxxYU6=
HEK 293	NEDOTnZHfW6ldHnvckBCe3OjeR?=	MX2xNEDPxE1?	M32w[lUhcA>?	M2PYZmROW09?	Mn3Kd5VxeHKnc4Pld{B1cGViQ2LUJIFkfGm4aYT5	NH32NI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOFM3Pid-MkSzNlQ{PjZ:L3G+
HL-60	NInxWXdHfW6ldHnvckBCe3OjeR?=	NWL0OoFZOTBxMkCg{txO	NFXlO3cyKGh?		NGPnV2NqdmirYnn0d{B1cGYEoF6uJINpcW6nboPpd4V5fHKjY4VCpIlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIHnueI8h\3KjboXsc4N6fGW\|	NGLsOYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO1O\|AzOCd-MkSzOVcxOjB:L3G+
HL-60	NV;YW2ZwTnWwY4Tpc44hSXO\|YYm=	MWSyJOK2VQ>?	MXixOkBp	MUfEUXNQ	MmPEbY5pcWKrdIOgeIhmKGG\|c3;jbYF1cW:wIH;mJJBUPjJzIGLh[k0yKGGwZDDOSmFV[zNuIHHu[EB1cGViUlGtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gcpVkdGWjcjDOSmFV[zN?	NVLqd3JNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|AxPjhpPkK0N\|MxODZ6PD;hQi=>
HeLa	NVXTTJZsTnWwY4Tpc44hSXO\|YYm=	NYLRZmxIPTBizszN	M4m1cFAvPSCq		M3j6SYJtd2OtczDUVnguOSCwdXPs[YFzKG2rZ4LheIlwdiCjbnSgWHhPUVBiZH;3ck1z\We3bHH0bY9v	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5NkiyO{c,OjR\|N{[4Nlc9N2F-
HUVECs	MmTDSpVv[3Srb36gRZN{[Xl?	NF7R[GgyOMLizszN	M1HvTlEhcA>?		NVOwTphMcW6qaXLpeJMhfGinIFjEUEBz\WS3Y3XkJGNQYC1{IHX4dJJme3Orb36gZY5lKFCJST2yJJJmdGWjc3W=	NXL4cXBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFUyODlpPkK0N\|g2OTB7PD;hQi=>
MCF-7	MV;GeY5kfGmxbjDBd5NigQ>?	NIjY[lAyOMLizszN	MXKxNE8{OCCvaX6=		MWny[YR2[2W\|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:\|cHjvdplt[XSrb36=	NGHZbWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO5NFgyQSd-MkSzPVA5OTl:L3G+
HGC-27	M2HIfmFxd3C2b4Ppd{BCe3OjeR?=	NGP4RVUyKML3TR?=	MkPoNUBp		NYHzNXNCe3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:\|cx?=	NYfLN\|M{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVY{PDlpPkK0OFE3OzR7PD;hQi=>
PC3	Ml3uRZBweHSxc3nzJGF{e2G7	MVe1NEDPxE1?	MnXKNE42KGh?		NYPR[Wp2cW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	M4r6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEK0PFg6Lz5{NESyOFg5QTxxYU6=
HPAEpiCs	Ml\vSpVv[3Srb36gRZN{[Xl?	NXvhPY94OzBizszN	MYWxJIg>		NUHiNpBrcW6qaXLpeJMhXE6ILd8xJJN1cW23bHH0[YQheDR{L4C0OEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR2MUi3NEc,OjR2NEG4O\|A9N2F-
BeWo	M1nqVGZ2dmO2aX;uJGF{e2G7	M1zmXlExyqEQvF2=	MonSNkBp		M3W0d4lvcGmkaYTzJGVTUzFxMh?=	M133e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOzPFQ3Lz5{NESzN\|g1PjxxYU6=
A498	MlTBRZBweHSxc3nzJGF{e2G7	MYC1NOKh\|ryP	NFHMUpMzPCCq		MkHtdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO=	M3;SbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUC4OFc3Lz5{NEWwPFQ4PjxxYU6=
NHBE	MYfGeY5kfGmxbjDBd5NigQ>?	MXGyM\|IxKM7:TR?=	MViyJIg>		NVTy[ZFr[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w	NX\aOmc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k2OjZpPkK0OFc6PTJ4PD;hQi=>
A375	NEjlT3pE\WyuIFnueoF{cW:wIFHzd4F6	MWqxNQKBmzJyINM1US=>	MWmyOEBp		NEHiTolz\WS3Y3XzJI1mdGGwb33hJINmdGxiaX72ZZNqd25?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR4NkCzOkc,OjR2Nk[wN\|Y9N2F-
HBMEC	NGDFc21HfW6ldHnvckBCe3OjeR?=	NW[yd\|BbOTBizszN	MmK4NUBp		NFS0bZpjdG:la4OgWmVITi2rbnT1Z4VlKEWyaFGyJIV5eHKnc4Ppc44>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3OEm4Nkc,OjR2NUi5PFI9N2F-
HCT-15	M3T0O2Z2dmO2aX;uJGF{e2G7		MVGxJIg>		NYPieZpj[XS2ZX71ZZRmeyCSR1WyMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGVzc8Li	MnnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{G0NlUoRjJ3NEOxOFI2RC:jPh?=
HCT-15	Mn:wRZBweHSxc3nzJGF{e2G7		MkXTNUBp		MWfhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{	NGizdoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzNVQzPSd-MkW0N\|E1OjV:L3G+
786-O	M1LXfWFxd3C2b4Ppd{BCe3OjeR?=	M{f2U\|UxyqEQvF2=	NX\McJppOjRiaB?=		MUTwc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?=	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEi0O\|YoRjJ2NUC4OFc3RC:jPh?=
HepG2	M1PuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLTcnp4OjBizszN	NFTpcWYzPCCq		NHXWeY1{fXCycnXzd4V{KFSJRj5OtlEucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44h[W6mIHnueoF{cW:w	M2SyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[wOFg5Lz5{NUW2NFQ5QDxxYU6=
SW480	NELJPGtHfW6ldHnvckBCe3OjeR?=	MlPhNlDDqM7:TR?=	NHPsR4QyyqCq		MXny[YR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=>	NFLYVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0O\|gyPid-MkW0OFc5OTZ:L3G+
MDA-MB-231	MWTGeY5kfGmxbjDBd5NigQ>?	M2izbVI2KM7:TR?=	NGfFc2gzNTNiaB?=		NVjjOlV2\GWlcnXhd4V{KHBvRWLLNU8zKGGwZDDTNVAxSTRiZYjwdoV{e2mxbh?=	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUW4O\|UoRjJ3NUW1PFc2RC:jPh?=
HepG2	MUjGeY5kfGmxbjDBd5NigQ>?	Ml3ONVAh\|ryP	MX61JIg>		MWPicI9kc3NicHjvd5Bpd3K7bHH0[YQhVUGSS4OgbY5lfWOnZDDifUBmgG:pZX7veZMhXEeILd8yNS=>	NFTr[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW2NFQ5QCd-MkW1OlA1QDh:L3G+
MCF-7	NXjzUGxHTnWwY4Tpc44hSXO\|YYm=	MoewNVAh\|ryP	MnnhNUBp		NV;aSYlKcW6qaXLpeJMhUUxvMUit[Y5p[W6lZXSgZ4VtdCCvaXfyZZRqd25?	M{TZN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K3NFEyLz5{NUeyO\|AyOTxxYU6=
H1355	NFPy[FNHfW6ldHnvckBCe3OjeR?=	MYqyOUDPxE1?	MnnyNUBp		M2PhcYJtfW62czD0bIUhSlujXWCtbY5lfWOnZDDpcoNz\WG\|ZTDpckBxcG:\|cHjvMWNpczFiYX7kJJBpd3OyaH:tSXJMKGW6cILld5Nqd25?	MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkmxPFEoRjJ3N{[5NVgyRC:jPh?=
PC12	MVXGeY5kfGmxbjDhd5NigQ>?				M{jlR2lvcGmkaYTpc44hd2ZibnXyeoUh\3Kxd4ToJIZi[3Sxcj3t[YRq[XSnZDDNRXAhc2mwYYPlJIFkfGm4aYT5JIlvKGi3bXHuJHBEOTJiY3XscJMtKEmFNUCgQUAzKM7:TT6=	MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyN{ezOlMoRjF6MEe3N\|Y{RC:jPh?=
HT-29	NGjqbpdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEjHO3g2KGSjeYO=		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy\|IHHmeIVzKDViZHH5d{BjgSCZU2SxJIF{e2G7LDDJR\|UxKD1iNDFOwG0v	Mnm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{izNVYoRjJ3MEe4N\|E3RC:jPh?=
IEC6	M{Pqb2Z2dmO2aX;uJIF{e2G7		MUe1JI1qdnN?		MnXxTY5pcWKrdHnvckBw\iCPRVuxM\|IhcW5icnH0JGlGSzZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUzFxMjDsc49xKHCqb4PwbI9zgWyjdHnvckBld3OnZDCzNEBucW6\|IHLl[o9z\SC2bzDzeIlufWyjdHnvckB4cXSqIEGwKUB{\XK3bTDmc5IhPSCvaX7zJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZDygTWM2OCB;IESuNkDPxE1w	MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyN{izNVYoRjJ3MEe4N\|E3RC:jPh?=
NG 108-15	NYi3S4NoTnWwY4Tpc44h[XO\|YYm=				MkT5R49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDhZo9tcXOqIF3BVGsh[WO2aY\peJkhcW5ibX;1d4UhdmW3cn;icIF{fG:vYTDhcoQhemG2IHfsbY9u[SCqeXLybYQhVkdiMUC4MVE2KGOnbHzzMEBC[3Srdnn0fUA:KDFyIN88UU4>	Mn;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV3M{ezOVQoRjF3NUO3N\|U1RC:jPh?=
PC12	MoHzSpVv[3Srb36gZZN{[Xl?	MXixNEB2VQ>?	NHLBcms2KGi{cx?=		NH7jeWZC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHnuJJJifCCSQ{GyJINmdGy\|IHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25iYYSgNVAhfU1iYX\0[ZIhPSCqcoOgdJJmfHKnYYTl[EB4cXSqIFrOT{BqdmirYnn0c5IhW1B4MECxNlUh\m:{IEGgbJIh[mWob4LlJINwdXCxdX7kJIFl\Gm2aX;uJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NImxdoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
PC12	M{\I[2Z2dmO2aX;uJIF{e2G7	MWGxNEB2VQ>?	NI[2Omk2KGi{cx?=		M4njOWFkfGm4YYTpc44hd2ZiToLmNk9CWkViaX6gdoF1KFCFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgTG8uOSCycn;0[YlvKGmwZIXjeIlwdiCjdDCxNEB2VSCjZoTldkA2KGi{czDwdoV1emWjdHXkJJdqfGhiTVXLNkBqdmirYnn0c5IhXTBzMk[g[o9zKDFiaIKgZoVnd3KnIHPvcZBwfW6mIHHk[Il1cW:wIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	M{CyVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{S1Olg2Lz5{MUO0OVY5PTxxYU6=
PC12	NFy3[ZRHfW6ldHnvckBie3OjeR?=	M3fhdFExKHWP	MU[1JIhzew>?		MUDBZ5RqfmG2aX;uJI9nKE6{ZkKvRXJGKGmwIILheEBRSzF{IHPlcIx{KGG\|c3Xzd4VlKGG\|IFjPMVEheHKxdHXpckBqdmS3Y4Tpc44h[XRiMUCgeW0h[W[2ZYKgOUBpenNicILleJJm[XSnZDD3bZRpKE2HS{GgbY5pcWKrdH;yJHBFQThyNUmg[o9zKDFiaIKgZoVnd3KnIHPvcZBwfW6mIHHk[Il1cW:wIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>?	NInIVI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
HeLa	NGLrZ\|RHfW6ldHnvckBie3OjeR?=	M3XCPVIxKHWP	NFiyXpc{KGi{cx?=		NEPmS5BKdmirYnn0bY9vKG:oIFXST\|EwOiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUGWOYTDj[YxteyCjdDCyNEB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz	MmPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{C2NVUoRjJ\|NUewOlE2RC:jPh?=
RD	MYnxTHRUKGG\|c3H5				NWflbGNjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MUTxTHRUKGG\|c3H5				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MoHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NWXQTZVGeUiWUzDhd5NigQ>?				Mo[zdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	M3zSRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	Mne2dWhVWyCjc4PhfS=>				NHLtOllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NUjUXYd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	MVzxTHRUKGG\|c3H5				NHvxcY9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MDA-MB-231	NVu5bVJ2TnWwY4Tpc44h[XO\|YYm=	NGTqW2s2OCC3TR?=			NIPrfoRFd3ewcnXneYxifGmxbjDv[kBOVVB{IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M2DXT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK2NlI3Lz5{MkmyOlIzPjxxYU6=
MDA-MB-231	Ml;CSpVv[3Srb36gZZN{[Xl?	MUK1NEB2VQ>?			NHTOWI9Fd3ewcnXneYxifGmxbjDv[kBOVVB7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYSgOVAhfU1iYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M4mzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK2NlI3Lz5{MkmyOlIzPjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT; PubMed: 17482134 Cancer cell ERK regulates c-Jun levels in melanoma. The indicated melanoma cell lines were treated with 50μM PD98059 (PD) or 10μM LY294002 (LY) for 12h in the absence of serum. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-JNK / JNK / Cyclin D1 ; PubMed: 17482134 Cancer cell Inhibition of the MEK/ERK pathway affects c-Jun, P-JNK and cyclin D1 levels. The indicated melanoma cell lines were treated with 50μM PD98059 for 16h. Protein samples were analyzed by Western blots using the indicated antibodies. α-Tubulin reveals equal loading. p-HER2 / HER2 ; PubMed: 24244023 J Immunol TE1cells were treated with wortmannin (Akt signal inhibitor), PD98059 (MAPK signal inhibitor), or lapatinib (EGFR and HER2 dual inhibitor) at the indicated doses or with DMSO as a negative control for 48 h. HER2-related signaling molecules were assessed by Western blot. MMP9 / XIAP / VEGF ; PubMed: 29695559 In Vivo SK-Hep1 cells were treated 10 μM PD98059 for 48 h. Protein levels of MMP-9, XIAP, VEGF, cyclin-D1, and pERK were evaluated with western blotting assay.	17482134 24244023 29695559

体内研究

在大脑缺血前30分钟用PD98059处理小鼠可以明显减轻伤害, 使脑梗塞的体积减小^[4]。基于胰腺的湿重和组织学研究发现，提前30分钟用PD98059预处理 (10 mg/kg 静脉注射) 然后每小时注射一次蛙皮素连续三次的小鼠可以明显改善蛙皮素诱导的急性胰腺炎^[7]。卡拉胶损伤一小时后用PD98059 (10 mg/kg) 对小鼠进行治疗可以发现与炎症相关的所有指标均有所下降^[11]。

激酶实验： ^[1]	- 合并体外MEK激酶活性测定: 在含有44-kDa GST-MAPK 或者45-kDa GST-MEK1的体系中检测³²P被掺入蛋白 MBP中的情况。反应体系50 μL ，含有50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP，加入10 μg GST-MEK1, 0.5 μg GST-MAPK和 40 μg MBP。30°C 孵育15 分钟, 加入Laemmli SDS 样品缓冲液终止反应。磷酸化的MBP 进行10% SDS-PAGE分析
细胞实验： ^[1]	- 合并 Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, 和K562 Concentrations: 溶于DMSO, 终浓度~100 μM Incubation Time: 3 天, 或者7-10天 Method: 细胞按10,000-20,000个/mL的密度接种在多孔平板中进行单层生长。48小时后把不同浓度的PD98059 加到细胞培养基孵育3天。然后通过胰酶将细胞从平板中消化下来并用Coulter 计数器计数。将细胞按5,000-10,000每皿的浓度接种在35 mm的培养皿中，培养基中含有0.3% 的琼脂和期望浓度的PD98059，让细胞在软琼脂上生长.经过7-10天的生长, 可以借助解剖显微镜将可见的菌落数出来。 (Only for Reference)
动物实验： ^[7]	- 合并 Animal Models: 患有急性胰腺炎的雄性Sprague–Dawley 大鼠 Dosages: 10 mg/kg Administration: 静脉注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	14 mg/mL warmed (52.37 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	1mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PD98059 SDF

分子量	267.28
化学式	C₁₆H₁₃NO₃
CAS号	167869-21-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
How to formulate this inhibitor for i.p. injection?
回答：
You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

泛MEK抑制剂

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM.
活性最高的MEK抑制剂

PD0325901 : MEK, IC50=0.33 nM.
FDA批准的MEK抑制剂

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
最新的MEK抑制剂

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

研究领域

产品类型

定制您的化合物库

PD98059

客户使用Selleck生产的PD98059发表文献386篇：

产品安全说明书

MEK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PD98059 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

相关MEK产品